Using augmented reality, Altoida is identifying the likely onset of neurodegenerative diseases | TechCrunch
Ioannis Tarnanas · Founder & Chief Science Officer of Altoida – Fyrfly Venture Partners | fyrfly.vc
Ioannis Tarnanas, PhD, MSc | Global Brain Health Institute
Ioannis Tarnanas · Founder & Chief Science Officer of Altoida – Fyrfly Venture Partners | fyrfly.vc
Ioannis Tarnanas - Worldwebforum
Altoida, Inc. - Contacts, Employees, Board Members, Advisors & Alumni
Ioannis Tarnanas - Worldwebforum
Ioannis Tarnanas, PhD, MSc | Global Brain Health Institute
Altoida - Diagnosing Alzheimer's Disease 5 years prior to it's onset using Augmented Reality on your iPhone | Startup Ranking
Dr. Ioannis Tarnanas, Ph.D. - Founder - Altoida, Inc. | LinkedIn
Using a Digital Neuro Signature to measure longitudinal individual-level change in Alzheimer's disease: the Altoida large cohort study | npj Digital Medicine
2018 EIT Innovators Award Winner Ioannis Tarnanas | EIT
A brain fitbit that can spot Alzheimer's with up to 94% accuracy
Altoida Raises $6.3 Million for Early, AI-Test for Alzheimer's Disease
Greek Researcher Receives Top European Innovation Award (video)
Ioannis Tarnanas Altoida Inc. - PMWC Precision Medicine World Conference
New Alzheimer's Prediction Smartphone App Gets FDA Breakthrough Status - Being Patient
Altoida secures funding and research partnership with Eisai Innovation – Venturelab
EIT Health - Ioannis Tarnanas is the winner of #EIT Innovators Award. He is CSO for Altoida- makers of ADPS, which can tell if someone will develop Alzheimer's disease within 6 years,
Ioannis Tarnanas Altoida Inc. - PMWC Precision Medicine World Conference
Venture Kick on Twitter: "Smart and personalized brain health gets a boost: TOP 100 Swiss startup @Altoida raises funding and cooperates with strategic investor @Eisai_SDGs from Japan. Congratulations to founder Ioannis Tarnanas
Alzheimer's detection platform Altoida raises $6.3M in Series A funding | MobiHealthNews
Using a Digital Neuro Signature to measure longitudinal individual-level change in Alzheimer's disease: the Altoida large cohort study | npj Digital Medicine
